

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

**KX-826 PHASE III CLINICAL TRIAL AND COMBINATION THERAPY
STUDY DATA FOR AGA PRESENTED AT THE 2026 WORLD
CONGRESS FOR HAIR RESEARCH (WCHR 2026), AND WAS
SELECTED AS AN OUTSTANDING POSTER**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest developments related to the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, its in-house developed and potential first-in-class KX-826 data from two important clinical studies was presented at the 14th World Congress for Hair Research (WCHR 2026) held in Seoul, South Korea from May 28 to 31, 2026:

(i) phase III clinical trial data for the treatment of male adult androgenetic alopecia (“**AGA**”) in China. Professor Cheng Zhou (周城) from Peking University People’s Hospital, the lead principal investigators of the phase III clinical trial, presented the final analysis results of KX-826 1.0% tincture for the treatment of male adult AGA in China at main venue. The overall results demonstrated that KX-826 exhibited excellent efficacy and safety in patients with AGA. Furthermore, the results of the phase III clinical trial were selected as an Outstanding Poster at WCHR 2026.

(ii) clinical observational study data in combination with minoxidil for the treatment of male adult AGA in China. The clinical observational study was led and completed by Professor Leiwei Jiang (江蕾微) and colleagues, and provided a solid basis for future phase III clinical trial of KX-826 and minoxidil combination therapy.

The WCHR is the the most influential academic conference in the global hair research field. Held biennially, it provides participants with a unique opportunity to delve into the outcomes of recent clinical trials and experimental studies.

Currently, the Company is actively advancing the marketing authorization application for KX-826. Upon approval, KX-826 is expected to become a first-in-class topical innovative drug, filling the current clinical gap for new drugs in AGA treatment and breaking the nearly 40-year treatment paradigm that has relied solely on minoxidil and finasteride.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: Apart from the cosmetic products of 826 topical anti-hair loss solution and acne cream, there is no assurance that other products of KX-826 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, 1 June 2026

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Dr. Xiang Ni; the non-executive Directors are Mr. Yunfei Chen and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

** For identification purpose only*